Nowadays, the improvement of the cardiorenal prognosis in patients with type 2 diabetes is largely independent of the current metabolic situation. The focus of patient-oriented treatment is on quality of life and organ protection. This is reflected in the current recommendations of the European and US diabetes societies (EASD/ADA) and in the practical recommendations of the German Diabetes Association (DDG). In addition, the European Society of Cardiology (ESC) has published evidence-based guidelines for the cardiorenal management of type 2 diabetics.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Physical activity with IBD
Sport is not murder, but it doesn’t help either
- White and Black Skin Cancer
Biology and Modern Therapeutic Approaches
- Highlights from the AAD Annual Meeting
Atopic Dermatitis: Interesting News on Drug Candidates in Phase III
- Autoimmune Liver Diseases
Innovative Treatment Approaches for PBC, PSC, and AIH: What’s New?
- Myelofibrosis
Mutations and Molecular Diagnostics in Treatment Decisions
- Psoriasis in the Age of Precision Medicine
Systemic Therapy for Patients with Comorbidities: What Is the Best Choice?
- The AMALFI study and the limits of digital screening for atrial fibrillation
Remote monitoring for atrial fibrillation: lots of detection, little stroke prevention?
- MASH